{"id":47633,"date":"2022-10-24T13:10:25","date_gmt":"2022-10-24T13:10:25","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=100605"},"modified":"2022-10-24T13:10:25","modified_gmt":"2022-10-24T13:10:25","slug":"taconic-biosciences-launches-first-and-only-super-immunodeficient-mouse-models-lacking-residual-murine-fc-gamma-receptors-for-improved-antibody-therapy-assessment","status":"publish","type":"post","link":"https:\/\/southafricahorizon.com\/taconic-biosciences-launches-first-and-only-super-immunodeficient-mouse-models-lacking-residual-murine-fc-gamma-receptors-for-improved-antibody-therapy-assessment\/","title":{"rendered":"Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment"},"content":{"rendered":"
\n

FcResolv\"\u2122\" NOG Models Provide Greater Clarity and More Translatable Data<\/h4>\n

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv\"\u2122\" NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (Fc\u03b3Rs) known to confound results in antibody-based therapy studies.<\/p>\n

Murine Fc\u03b3Rs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery. FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals. With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.<\/p>\n

\u201cAntibody-based therapies represent one of the fastest-growing classes of drugs, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies,\u201d said Dr. Michael Seiler, vice president of commercial products at Taconic. \u201cTaconic\u2019s FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.\u201d<\/p>\n

FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic\u2019s Fc domain interacts with murine Fc\u03b3Rs as well as the false positives that result when Fc\u03b3Rs trigger residual murine immune activity. They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system. With more reliable answers, researchers can target their drug discovery investments more strategically and effectively.<\/p>\n

The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse\u00ae<\/sup>. The portfolio currently includes two models:<\/p>\n